STATEMENT ON THE AVAILABILITY AND QUALITY OF MEDICINES IN KENYA

The Pharmacy and Poisons Board (PPB) of Kenya recently issued a statement refuting claims of an impending national medicine crisis due to the alleged blocking of over 21,000 medical products. The Board clarified that approximately 9,000 registered health products and technologies meet national and international standards and remain available for manufacture, importation, and distribution. This statement comes amidst ongoing efforts by the PPB to strengthen pharmaceutical regulation, including a mandatory five-year renewal process for marketing authorizations and a concerted fight against unregistered, falsified, and substandard medicines. The development underscores Kenya's commitment to enhancing medicine quality and availability, aligning with its goal to achieve World Health Organization (WHO) Maturity Level 3 status in pharmaceutical regulation, while also navigating persistent challenges in supply chain integrity and access to essential medicines.

The pharmaceutical landscape in Kenya has recently been subject to significant public discourse, following a press statement from the Pharmacy and Poisons Board (PPB) on October 5, 2025. The statement directly addressed and refuted what it termed "misleading" social media allegations that the Board intended to "block over 21,000 medical products," thereby placing the country "on the brink of a medicines crisis." This clarification by the national medicines regulatory authority is crucial for maintaining public confidence and ensuring the stability of the medicine supply chain. The PPB asserted that, contrary to these claims, there is no blockade of medicines, and approximately 9,000 duly registered medical products, meeting stringent national and international standards, remain accessible in the Kenyan market.

This article delves into the legal and regulatory context surrounding the PPB's statement, examining the statutory framework governing medicine quality and availability in Kenya. It will analyze the Board's ongoing regulatory reforms, including the mandatory renewal of marketing authorizations, and place these efforts within the broader national objective of strengthening pharmaceutical oversight. Furthermore, the article will explore the persistent challenges faced by Kenya in ensuring consistent access to safe and effective medicines, including issues related to counterfeit products and supply chain vulnerabilities, and the implications for legal practitioners operating within this dynamic environment.

The regulation of pharmacy practice and the trade in drugs and poisons in Kenya is primarily governed by the Pharmacy and Poisons Act, Cap 244 of the Laws of Kenya. This foundational legislation established the Pharmacy and Poisons Board (PPB) as the National Medicines Regulatory Authority, tasked with a broad mandate to ensure that all Health Products and Technologies (HPTs) available in the country are of assured quality, safety, and efficacy. The Act outlines provisions for the registration of pharmacists, the preparation of a Poisons List, licensing for the manufacture of medicinal substances, and strict controls over the advertisement of drugs.

Under its statutory powers, the PPB is responsible for the registration of medical products, a critical process that ensures only products meeting specified standards enter the Kenyan market. In line with global regulatory best practices, and as stipulated by the Pharmacy and Poisons (Registration of Health Products and Technologies) Rules, 2022, all marketing authorizations are subject to renewal every five years. This periodic renewal process is designed to allow the Board to re-evaluate products against current international standards, thereby continuously safeguarding public health by removing any products that no longer meet the required benchmarks for quality, safety, and efficacy. The Board also operates a National Quality Control Laboratory, established under Part IIIB of the Pharmacy and Poisons Act, to conduct post-marketing surveillance and quality control testing of medicines.

The PPB's recent statement directly addressed concerns raised by the Kenya Pharmaceutical Distributors Association, which had warned of a potential shortage after the Board reconfigured its importation portal in preparation for a World Health Organization (WHO) audit. The PPB clarified that the ongoing renewal process for marketing authorizations, a standard regulatory practice, was misinterpreted as a "blockade." The Board affirmed that approximately 9,000 registered medical products continue to be available, ensuring no cause for concern regarding medicine shortages. This proactive communication highlights the PPB's commitment to transparency and its role in dispelling misinformation that could disrupt public confidence in the pharmaceutical supply chain.

These regulatory actions are intrinsically linked to Kenya's ambitious goal of achieving WHO Maturity Level 3 (ML3) status in pharmaceutical regulation by December 2026. Attaining ML3 signifies a stable and well-functioning regulatory authority capable of guaranteeing the safety, efficacy, and quality of all medicines. The renewal process, coupled with enhanced surveillance and enforcement, is a key component of this broader strategy. The government has also launched an Interministerial Steering Committee to implement a National Action Plan on Substandard and Falsified (SF) Medical Products, demonstrating a coordinated "whole-of-government approach" to combat this threat. Furthermore, the PPB has deployed advanced Near Infrared Technology (NIR), known as Pillscan, to enhance on-site quality control and detect SF medical products at regional offices and entry points.

Despite these advancements, Kenya continues to grapple with challenges in ensuring consistent access to quality medicines. Reports indicate weaknesses in medicine financing, fragmented county-level supply systems, and a heavy reliance on imported pharmaceuticals, with only about 20% of medicines on the Kenya Essential Medicines List produced locally. A significant legal hurdle has been the Anti-Counterfeit Act, 2008. Its broad definition of "counterfeit" initially posed a threat to the availability of affordable generic medicines, leading to a landmark High Court decision in 2012 (Patricia Asero Ochieng and 2 Others v. Attorney General) that found certain sections unconstitutional for infringing on the right to life, dignity, and health. This ruling necessitated a review of the Act to clearly distinguish between counterfeit and generic medicines. Recent proposed amendments to the Anti-Counterfeit Act aim to explicitly outlaw the fraudulent mislabeling of medicines, further strengthening the fight against fake medical products. The ongoing regulatory reforms, including the planned nationwide digital "track and trace" system, are critical steps towards addressing these multifaceted challenges and ensuring a robust and secure pharmaceutical supply chain.

The Pharmacy and Poisons Board's recent statement underscores a critical juncture in Kenya's pharmaceutical regulatory journey. While actively dispelling misinformation about medicine shortages, the Board is concurrently implementing robust measures to enhance the quality, safety, and availability of health products. The mandatory five-year renewal of marketing authorizations, the pursuit of WHO Maturity Level 3 status, and the deployment of advanced technologies like Pillscan signal a determined effort to fortify the regulatory framework and combat substandard and falsified medicines. These initiatives, coupled with the establishment of an Interministerial Steering Committee and proposed amendments to the Anti-Counterfeit Act, demonstrate a comprehensive approach to safeguarding public health.

For legal practitioners, these developments necessitate a keen understanding of the evolving regulatory landscape. Compliance with the Pharmacy and Poisons Act, Cap 244, and its subsidiary legislation, particularly the 2022 Rules on registration and renewal, is paramount for all market authorization holders and pharmaceutical stakeholders. Practitioners must also remain vigilant regarding the implications of the Anti-Counterfeit Act and its amendments, ensuring that clients' operations align with the nuanced distinction between genuine generics and illicit counterfeits. The ongoing reforms, including the digital track and trace system, will introduce new compliance requirements and enforcement mechanisms. Monitoring the progress towards WHO ML3 status and the effectiveness of the National Action Plan on Substandard and Falsified Medical Products will be crucial for advising clients on navigating Kenya's increasingly stringent pharmaceutical regulatory environment.